Completed PHASE4 INTERVENTIONAL 2-arm NCT00735449

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects

Sponsor: Allergan

Interventions Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% latanoprost 0.005% timolol maleate 0.5%

Updated 10 times since 2017 Last updated: Apr 10, 2019 Started: Jul 31, 2008 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00735449, this PHASE4 trial focuses on Glaucoma and Ocular Hypertension and remains completed. Sponsored by Allergan, it has been updated 10 times since 2008, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

10 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4

▶ Show 5 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE4
May 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — May 2019 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada
• Newark, United States